FDA Approval Of Cimzia(R) For Crohn’s Disease Represents Latest Milestone For Nektar’s PEGylation Technology Platform
May 15th 2008Drug InformationCrohn
The U.S. Food and Drug Administration (FDA) approved UCB’s Cimzia(R) (certolizumab pegol) for reducing the signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) is the first and only PEGylated Fab’ fragment of a humanized anti-TNF-alpha antibody approved by the FDA.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
